Treatment of Kimura Disease with Tumor Under 3 cm and Symptom Duration Under 5 Years

In patients with confirmed Kimura disease, a specific clinical profile — small tumor size, early disease, low peripheral blood eosinophilia, and serum IgE below 10,000 IU/ml — defines a subgroup for whom evidence from meta-analysis supports a distinct primary treatment approach.

Clinical Criteria for This Protocol

Maximal tumor diameter less than 3 cm
Symptom duration less than 5 years
Peripheral blood eosinophilia less than 20%
Serum IgE level less than 10,000 IU/ml

Treatment approach: For patients meeting all four of these criteria, the evidence points to a surgical intervention as the preferred primary treatment — the complete structured regimen is available via the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.ijsu.2022.106591

Meta-analysis revealed that surgical excision is a preferred primary treatment if pathology of KD is confirmed.

Surgery was an effective single treatment modality for patients with tumors smaller than 3 cm (POR = 2.89, 95% CI: 1.20–6.95; p = 0.02), symptom duration shorter than 5 years (POR = 3.11, 95% CI, 1.03–9.38; p = 0.04), peripheral blood eosinophilia less than 20% (POR = 4.49, 95% CI: 1.46–13.84; p = 0.009) or serum IgE level less than 10000 IU/ml (POR = 8.30, 95% CI: 1.05–65.34; p = 0.04).

View source ↗